Mixed Chimera Allogeneic Transplantation With or Without Allogeneic Idiotyped Pulsed Dendritic Cells for the Treatment of Multiple Myeloma
To determine toxicity and feasibility of mixed chimera allogeneic hematopoietic cell transplants for multiple myeloma; prepare and vaccinate patients with allogenic dendritic cell vaccinations following mixed chimera allogeneic hematopoietic cell transplants
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : cyclophosphamide
- drug : Melphalan
- drug : cyclosporin
- drug : Mycophenolate mofetil
- procedure : autologous then nonmyeloablative allogeneic transplant
Phase: Phase 2
Ages Eligible For Study:
- Multiple myeloma. Eligible patients may have early or relapsed disease. Patients must have Stage II-III disease or have progression after initial treatment of Stage I disease. - Age less than or equal to 70 years. - No prior therapy which would preclude the use of low-dose total body irradiation. - Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. Patients with smoldering multiple myeloma, monoclonal gammopathy of unknown significance, or primary amyloidosis will be excluded from this study. - Patients must have a Karnofsky performance status greater than 70%. - DLCO >=60% predicted. - ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl. - Serum creatinine < 2.0 or 24-hour creatinine clearance >=60 ml/min. - Patients must be HIV negative. - Pregnant or lactating women will not be eligible to participate. - Patients must provide signed, informed consent. - Patients must have an HLA-identical sibling donor.